

interpretation of available toxicological information and epidemiologic evaluations. This information and these data are to be used to ascertain the levels of significant human exposure for the substance and the associated health effects. The profiles must also include a determination of whether adequate information on the health effects of each substance is available or in the process of development. When adequate information is not available, ATSDR, in cooperation with the National Toxicology Program (NTP), is required to assure the initiation of research to determine these health effects.

Although key studies for each of the substances were considered during the profile development process, this **Federal Register** notice seeks to solicit any additional studies, particularly unpublished data and ongoing studies, which will be evaluated for possible addition to the profiles now or in the future.

The following draft toxicological profiles will be made available to the public on or about October 17, 1997.

Docu- ment	Hazardous sub- stance	CAS No.
1.	CADMIUM CADMIUM CAR- BONATE. CADMIUM CHLO- RIDE. CADMIUM OXIDE CADMIUM SUL- FATE. CADMIUM SUL- FIDE.	007440-43-9 000513-78-0 010108-64-2 01306-19-0 010124-36-4 01306-23-6
2.	CHLORODIBENZ- O-P-DIOXIN. DICHLORODIBEN- ZO-P-DIOXIN. HEPTACHLOROD- IBENZO-P- DIOXIN. HEXACHLORODI- BENZO-P- DIOXIN. OCTACHLORODI- BENZO-P- DIOXIN. PENTACHLOROD- IBENZO-P- DIOXIN. TRICHLORODIBE- NZO-P-DIOXIN. TETRACHLOROD- IBENZO-P- DIOXIN. 1,2,3,4,6,7,8- HEPTACHLOR- ODIBENZO-P- DIOXIN.	039227-53-7 050585-39-2 037871-00-4 034465-46-8 003268-87-9 036088-22-9 039227-58-2 041903-57-5 035822-46-9
3.	CHLOROPHENO- LS. 2,3,5,6- TETRACHLOR- OPHENOL.	000088-06-2 000935-95-5

Docu- ment	Hazardous sub- stance	CAS No.
	2,4,5- TRICHLOROPH- ENOL. 2,4,6- TRICHLOROPH- ENOL. 2- CHLOROPHEN- OL. 4-Chlorophenol 2,3,4,5- TETRACHLOR- OPHENOL. 2,3,4,6- TETRACHLOR- OPHENOL. 4. DORMALDEHYDE 5. HEXACHLOROC- YCLOHEXANE. HEXACHLOROC- YCLOHEXANE, ALPHA-. HEXACHLOROC- YCLOHEXANE, BETA-. HEXACHLOROC- YCLOHEXANE, DELTA-. HEXACHLOROC- YCLOHEXANE, GAMMA-. 6. HEXACHLOROC- YCLO- PENTADIENE. 7. MANGANESE 8. HYDROGEN SUL- FIDE.	000095-95-4 000088-06-2 000120-83-2 000095-57-8 004901-51-3 000058-90-2 000050-00-0 000608-73-1 000319-84-6 000319-85-7 000319-86-8 000058-89-9 000077-47-4 007439-96-5 007783-06-4

All profiles issued as "Drafts for Public Comment" represent ATSDR's best efforts to provide important toxicological information on priority hazardous substances. We are seeking public comments and additional information which may be used to supplement these profiles. ATSDR remains committed to providing a public comment period for these documents as a means to best serve public health and our clients.

Dated: October 22, 1997.

Georgi Jones,

*Director, Office of Policy and External Affairs,
Agency for Toxic Substances and Disease
Registry.*

[FR Doc. 97-28476 Filed 10-27-97; 8:45 am]

BILLING CODE 4163-70-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, National Center for Infectious Diseases: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Board of Scientific Counselors, National Center for Infectious Diseases (NCID).

Times and Dates: 11 a.m.-5:15 p.m., December 4, 1997; 8:30 a.m.-2:30 p.m., December 5, 1997.

Place: CDC, Auditorium B, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: The Board of Scientific Counselors, NCID, provides advice and guidance to the Director, CDC, and Director, Page 2 NCID, in the following areas: program goals and objectives; strategies; program organization and resources for infectious disease prevention and control; and program priorities.

Matters to be Discussed: Agenda items will include:

1. NCID Update
 2. Overview of CDC Emerging Infections Plan, 1998-2003
 3. Charge to the Workgroups
 4. Workgroup Sessions:
CDC Plan:
 - a. Surveillance and Response
 - b. Applied Research
 - c. Prevention and Control
 - d. Infrastructure Bioterrorism Preparedness
 5. Workgroup Reports
 6. Facilities Update
 7. Scientific Updates (Late breakers)
 8. Recommendations
- Other agenda items include announcements/introductions; follow-up on actions recommended by the Board in May 1997; Page 3 and consideration of future directions, goals, and recommendations. Agenda items are subject to change as priorities dictate.

Written comments are welcome and should be received by the contact person listed below prior to the opening of the meeting.

Contact Person for More Information:

Diane S. Holley, Office of the Director, NCID, CDC, Mailstop C-20, 1600 Clifton Road, NE, Atlanta, Georgia 30333, telephone 404/639-0078.

Dated: October 22, 1997.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-28480 Filed 10-27-97; 8:45 am]

BILLING CODE 4163-18-P